Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 15/20 | 0.47 |
| ▸ | AR | P10275 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3850276 | 0.92 | VDR (0.59) | VDRAR | |
| SCHEMBL3855866 | 0.91 | VDR (0.49) | VDRARKDM4EALDH1A1 | |
| SCHEMBL3851230 | 0.88 | VDR (0.45) | VDRAR | |
| SCHEMBL13713993 | 0.85 | VDR (0.50) | VDRARKDM4EALDH1A1 | |
| SCHEMBL3850804 | 0.84 | VDR (0.59) | VDRAR | |
| SCHEMBL3853020 | 0.82 | ESR1 (0.49) | TP53POLBTHRBSMN1; SMN2KDM4E | |
| SCHEMBL3859969 | 0.82 | VDR (0.61) | VDRAR | |
| SCHEMBL3851349 | 0.80 | VDR (0.58) | VDRAR | |
| SCHEMBL3855199 | 0.79 | VDR (0.47) | VDRAR | |
| SCHEMBL3860206 | 0.79 | VDR (0.54) | VDRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579488-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106095-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106095-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | VDR 1/4885AR 437/4885TP53 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.